Evidence map›Paper›PMID 38639872›Full record

ArticleDiscover oncology2024

SLC35A2 expression is associated with HER2 expression in breast cancer.

Yiran Wang, Xiaobo Peng, Meihong Wu, Bin Wang, Tianran Chen, Xianbao Zhan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yiran Wang *Department of Oncology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Xiaobo Peng *Department of Oncology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Meihong Wu *Department of Oncology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Bin WangDepartment of Oncology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Tianran ChenDepartment of Oncology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Xianbao ZhanDepartment of Oncology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China. zhan.xianbao@smmu.edu.cn.
Changhai Hospital · CNSecond Military Medical University · CN

Funding

234 discipline peak climbing program of Shanghai Changhai Hospital 2019YXK019Basic Medical Research Project of Navy Medical University 2022QN055
6 · The paper itself

Abstract

The role of SLC35A2 in breast cancer remains poorly understood, with limited available information on its significance. This study aimed to investigate the expression of SLC35A2 and clinicopathological variables in breast cancer patients. Immunohistochemical analysis of SLC35A2 protein was conductedon 40 adjacent non-neoplastic tissues and 320 breast cancer tissues. The study also assesed the association between SLC35A2 expression and breast cancer clinicopathological features of breast cancer, as well as its impact on overall survival. In comparison to adjacent non-neoplastic tissues, a significantly higher expression of SLC35A2 was observed in breast cancer tissues (P = 0.020), and this expression was found to be independently correlated with HER2 positivity (P = 0.001). Survival analysis indicated that patients with low SLC35A2 expression had a more favorable prognosis in HER2-positive subtype breast cancer (P = 0.017). These results suggest that SLC35A2 is overexpressed in breast cancer tissues compared to adjacent non-neoplastic tissues and may serve as a potential prognostic marker for HER2-positive subtype breast cancer. Furthermore, breast cancer patients with the HER2 positive subtype who exhibited decreased levels of SLC35A2 expression demonstrated improved long-term prognostic outcomes.

Indexed as

Breast cancerHER2ImmunohistochemistryPrognosisSLC35A2

Identifiers

PMID38639872
PMCPMC11031507
OpenAlexW4394962411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.